Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Source:
Nasdaq GlobeNewswire
/
09 Oct 2023 08:00:00 America/New_York
N/A
Share on,